Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis.
Brenu, Ekua W, van Driel, Mieke L, Staines, Donald R et al. · Journal of translational medicine · 2012 · DOI
Quick Summary
This study tracked immune system changes in 65 people with ME/CFS over one year, comparing them to 21 healthy controls. Researchers found that people with ME/CFS had consistently lower natural killer (NK) cell activity—immune cells that help fight infections—throughout the year. They also found changes in inflammatory molecules called cytokines that fluctuated at different time points.
Why It Matters
This research identifies persistent immune dysfunction in ME/CFS and suggests NK cell activity could be a reliable biological marker for diagnosis—important because ME/CFS currently lacks a specific diagnostic test. Understanding which immune abnormalities remain stable over time helps researchers distinguish core disease mechanisms from secondary changes and could guide development of targeted treatments.
Observed Findings
NK cell cytotoxic activity was significantly decreased in CFS/ME patients compared to controls at all three timepoints (baseline, 6 months, 12 months).
CD56brightCD16− NK cell numbers were significantly lower in CFS/ME patients at baseline and 6 months, but partially recovered by 12 months.
Cytokine secretion patterns differed: IL-10, IFN-γ, and TNF-α were elevated at baseline in CFS/ME patients; IL-10 and IL-17A decreased by 6 months; IL-2 was increased at 12 months.
Overall NK cytotoxic activity significantly declined from baseline to 12 months within the CFS/ME group.
CD56brightCD16− NK cells were lowest at 6 months compared to baseline and 12 months.
Inferred Conclusions
Decreased NK cell cytotoxicity is a persistent and consistent feature of CFS/ME that may serve as a suitable biomarker for diagnosis.
CFS/ME patients show evidence of immune dysfunction that could increase susceptibility to viral and other infections.
Immune abnormalities in CFS/ME are not static but show temporal variation over the 12-month period.
Remaining Questions
What drives the temporal fluctuations in cytokine levels and NK cell subsets, and what clinical factors correlate with these changes?
Does NK cell cytotoxicity correlate with symptom severity, disease duration, or patient outcomes?
What This Study Does Not Prove
This study does not establish that reduced NK cell activity causes ME/CFS or determine whether immune changes lead to symptom severity. The study also cannot explain why cytokine levels fluctuated differently at different timepoints, and correlations observed do not prove causation of infections or other complications in ME/CFS patients.